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Abstract
Introduction:  Aspirin-exacerbated  respiratory  disease  (AERD)  consists  of  a  classic  tetrad:  mod-
erate/severe  asthma,  chronic  rhinosinusitis,  nasal  polyps,  and  intolerance  to  aspirin  or  other
nonsteroidal  anti-inﬂammatory  drugs.  Clinical  control  with  drugs,  surgery,  and  desensitization
are treatment  options.
Objective:  To  evaluate  the  efﬁcacy  and  tolerability  of  aspirin  desensitization  in  patients  with
AERD.
Methods: Periodic  symptom  assessment  and  endoscopy  in  patients  with  AERD  undergoing
surgery who  were  desensitized.
Results:  Seventeen  patients  were  desensitized.  Eight  patients  completed  the  desensitization
and were  followed  for  a  minimum  of  a  one-year  period  (mean  3.1  years).  These  patients  showed
improvement  in  all  symptoms.  Moreover,  surgical  reassessment  was  not  indicated  in  any  of  these
patients and  there  was  a  decrease  in  costs  with  medication  and  procedures.  Eight  patients  did
not complete  desensitization,  mainly  due  to  procedure  intolerance  and  uncontrolled  asthma,
whereas another  patient  was  lost  to  follow-up.
Conclusion:  Aspirin  desensitization,  when  tolerated,  was  effective  in  patients  with  AERD  and
with poor  clinical/surgical  response.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published  by
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PALAVRAS-CHAVE
Dessensibilizac¸ão
imunológica;
Aspirina;
Sinusite;
Polipose  nasal
O  papel  da  dessensibilizac¸ão  à  aspirina  em  pacientes  portadores  de  doenc¸a
respiratória  exacerbada  por  aspirina  (DREA)
Resumo
Introduc¸ão:  A  doenc¸a  respiratória  exacerbada  por  aspirina  é  composta  pela  tétrade  clás-
sica: asma  moderada/grave,  rinossinusite  crônica,  pólipos  nasais  e  intolerância  à  aspirina
ou outro  anti-inﬂamatório  não  esteroide.  Controle  clínico  com  medicamentos,  cirurgias  e
dessensibilizac¸ão são  opc¸ões  de  tratamento.
Objetivo:  Avaliar  a  eﬁcácia  e  tolerabilidade  da  dessensibilizac¸ão  à  aspirina  em  pacientes  com
doenc¸a exacerbada  por  aspirina.
Método:  Avaliac¸ão  periódica  dos  sintomas  e  exame  endoscópico  em  pacientes  com  doenc¸a
respiratória  exacerbada  por  aspirina  submetidos  à  cirurgia  e  dessensibilizados.
Resultados:  Dezessete  pacientes  foram  dessensibilizados,  dos  quais  oito  pacientes  comple-
taram a  dessensibilizac¸ão  e  foram  acompanhados  pelo  tempo  mínimo  de  1  ano  (média  de
3,1 anos).  Todos  referiram  melhora  de  todos  os  sintomas;  não  houve  nenhuma  indicac¸ão  de
reabordagem  cirúrgica,  e  houve  reduc¸ão  de  gastos  com  medicac¸ões  e  procedimentos.  Out-
ros oito  pacientes  não  completaram  a  dessensibilizac¸ão,  principalmente  por  intolerância  ao
procedimento  e  descontrole  da  asma,  enquanto  outro  paciente  perdeu  o  seguimento.
Conclusão:  A  dessensibilizac¸ão  à  aspirina,  quando  tolerada,  mostrou-se  eﬁcaz  nos  pacientes
com doenc¸a  respiratória  exacerbada  por  aspirina  com  resposta  clínica/cirúrgica  insatisfatória.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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spirin-exacerbated  respiratory  disease  (AERD),  also
escribed  in  the  literature  as  Samter’s  triad  and  aspirin-
nduced  asthma  (AIA),  is  a  clinical  syndrome  whose
ymptoms  are  induced  by  a  non-allergic  hypersensitiv-
ty  reaction,  independent  of  IgE,1--5 to  aspirin  and/or
ther  non-steroidal  anti-inﬂammatory  drugs  (NSAIDs),
yclooxygenase-1  (COX-1)  enzyme  inhibitors.  It  was  origi-
ally  described  by  Widal  et  al.6 in  1922  and  by  Samter  and
eer7 in  1967.  The  classical  presentation  comprises  the
etrad:  moderate  to  severe  asthma,  chronic  hypertrophic
osinophilic  rhinosinusitis,  sinonasal  polyps,  and  intolerance
o  aspirin  or  other  NSAIDs.1
Symptom  onset  usually  occurs  in  adulthood,  usually
efore  the  age  of  40,1,3 and  the  number  of  affected  women
s  higher  than  that  of  men.1,2 There  is  no  described  asso-
iation  with  ethnicity  and  family  history  is  rarely  present.3
tudies  show  that  its  prevalence  in  the  general  population
s  0.3%--0.9%,  reaching  10%--20%  in  patients  with  asthma,
ffecting  30%--40%  of  asthmatics  with  nasal  polyposis  and
hronic  rhinosinusitis.1,3
The  physiopathology  of  AERD  is  not  fully  known.  The
rst  theory,  proposed  by  Szczeklik  in  1988,  associated  a
iral  respiratory  infection  as  a  trigger  for  AERD.4 More
ecent  studies  have  shown  the  release  of  cytokines  in  vitro
y  lymphocytes  infected  with  respiratory  syncytial  virus,
arainﬂuenza  virus,  and  rhinovirus.  Cytokines  recruit,  stim-
late,  and  activate  inﬂammatory  cells.4,5Another  factor  appears  to  be  the  increased  expression
f  speciﬁc  cytokines  associated  with  activation  and  sur-
ival  of  eosinophils  in  nasal  polyps,  such  as  interleukin  5
IL-5),  GM-CSF  (granulocyte-macrophage  colony-stimulating
H
w
iactor),  and  eotaxin,  which  would  increase  the  intensity  of
ocal  eosinophilic  inﬂammation.
It  is  believed  that  patients  with  AERD  have  genetic
olymorphisms  that  lead  to  reduced  activity  of  the  COX-1
soenzyme  and  increased  afﬁnity  of  leukotriene  recep-
ors,  with  low  production  of  PGE2  (prostaglandin  E2)
nd  low  COX-2  expression  in  nasal  polyps.  Since  PGE2
as  anti-inﬂammatory  activity,  the  inhibition  of  eosinophil
hemotaxis  and  its  activation,  and  a  decreased  production
f  this  prostaglandin  (PG)  would  contribute  to  the  devel-
pment  of  more  severe  eosinophilic  inﬂammation.  These
lterations  in  the  arachidonic  acid  metabolism  lead  to  an
mbalance  in  the  PG/leukotriene  ratio  in  these  patients,
ausing  inﬂammatory  alterations  in  the  upper  and  lower
irways.8--11
The  ingestion  of  aspirin  (acetylsalicylic  acid)  or  NSAIDs
y  a  sensitive  patient  inhibits  COX-1  and  results  in  the
xacerbation  of  the  inﬂammation  already  present  in  the
pper  and  lower  airways,  with  a  wide  spectrum  of  sever-
ty  and  manifestations  that  range  from  conjunctivitis  and
hinitis  to  laryngospasm  and  bronchospasm.1 Initially,  the
linical  manifestation  of  AERD  is  nasal  congestion,  which
ay  be  reported  by  the  patient  as  an  upper-airway  viral
nfection  that  never  resolved.  Hyposmia  or  anosmia  occurs
n  most  patients  with  AERD.3 This  rhinitis  develops  into
hronic  hypertrophic  eosinophilic  pansinusitis  and  emer-
ence  of  nasal  polyps,  which  recur  even  after  surgical
xcision.  Asthma  may  already  be  present  from  childhood
r  young  adulthood,  or  occur  after  three  months  to  ﬁve
ears  of  symptom  onset,  and  is  usually  moderate  to  severe.
ypersensitivity  skin  tests  are  usually  negative  in  patients
ith  AERD,  indicating  higher  prevalence  in  non-atopic
ndividuals.12
xace
b
1
I
p
p
1
m
o
p
a
b
c
d
e
t
1
2
3
a
p
s
aThe  role  of  aspirin  desensitization  in  patients  with  aspirin-e
History  of  asthma  triggered  by  ingestion  of  aspirin  or
other  NSAIDs  is  suggestive  of  AERD.  The  challenge  test  is  the
gold  standard  for  the  diagnosis.1--5,11 The  oral  route  is  the
most  used,  because  it  is  more  sensitive  and  its  speciﬁcity
is  similar  to  that  of  the  nasal,  bronchial,  and  intravenous
routes.
The  management  of  patients  diagnosed  with  AERD
includes  nasal  surgeries,  ASA  desensitization,  and  rec-
ommendations  on  how  to  completely  avoid  the  use  of
non-selective  COX  inhibitors.  For  those  making  this  choice,
it  is  necessary  to  have  full  knowledge  of  all  the  drugs  that
inhibit  this  pathway,  including  those  with  cross-reactivity.  It
is  noteworthy  that  selective  inhibitors  of  COX-2  can  be  used
in  patients  with  AERD;  however,  due  to  the  albeit  remote
possibility  of  cross-reactions,  it  is  recommended  that  the
ﬁrst  dose  of  these  drugs  be  administered  in  a  private  clinic
or  hospital.1
However,  even  if  they  avoid  the  use  of  COX-1  inhibitors,
patients  with  AERD  usually  have  progressive  worsening  of
respiratory  disease,  even  with  aggressive  surgical  treat-
ment  and  topical  and/or  systemic  corticosteroids  and
anti-leukotrienes.2,13--15 It  is  also  noteworthy  that  avoiding
the  use  of  aspirin  is  not  always  possible,  as  in  cardiovascu-
lar  disease  management.  The  chance  of  recurrence  of  nasal
polyposis  and  the  need  for  new  endoscopic  paranasal  sinus
surgery  (EPSS)  is  high  in  patients  with  AERD,  compared  with
patients  with  nasal  polyposis  who  are  tolerant  to  aspirin.16
Currently,  there  is  no  biomarker  that  can  predict  the  dis-
ease  and  airway  remodeling  activity.  Recently,  there  have
been  studies  that  identiﬁed  serum  periostin  increases  as
a  useful  biomarker  for  the  assessment  of  airﬂow  limita-
tion  in  asthmatic  patients,  indicating  Th2  inﬂammatory
response.17,18
The  aim  of  the  study  was  to  evaluate  the  effectiveness
of  ASA  desensitization  in  patients  with  AERD  treated  at  the
Rhinosinusology  Clinic,  as  well  as  their  tolerance  to  the  pro-
cedure.
Methods
The  study  was  approved  by  the  Research  Ethics  Com-
mittee,  Process  No.  13091313.7.0000.5440.  Patients  who
had  chronic  rhinosinusitis  with  nasal  polyps  (CRSwNP),
moderate/severe  asthma,  and  history  compatible  with
hypersensitivity  to  aspirin  were  evaluated  from  2008  to
2013.  The  patients  remained  moderately  symptomatic  even
if  submitted  to  short  pulses  of  systemic  corticosteroids,  top-
ical  corticosteroid  therapy  (both  applications  in  each  nostril
twice  a  day),  and  antileukotriene  once  a  day.  All  under-
went  oral  challenge  test  with  ASA,  according  to  the  speciﬁc
service  protocol,  establishing  the  diagnosis  of  AERD.  Of
these,  16  accepted  the  ASA  desensitization  protocol,  which
was  conducted  at  the  Hospital  Allergy  and  Immunology
Clinic.  Four  weeks  after  EPSS,  patients  were  hospitalized,
properly  advised  on  the  need  for  the  procedure,  and  signed
the  informed  consent.Desensitization  protocol
Initially,  venous  access  was  performed  through  a  peripheral
vein.  The  following  medications  were  available  at  the
m
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edside  for  any  systemic  reaction:  methylprednisolone
25  mg  IV,  salbutamol  nebulizer  (10--20  gts),  ranitidine  50  mg
V  or  cimetidine  300  mg  IV,  adrenaline  1:1000  0.3  mL  IM,  and
romethazine  50  mg  (1  amp)  IV.  The  pre-medications  were
rednisone  20  mg  every  12  h  and  montelukast  (SingulairTM)
0  mg  every  12  h,  48  h  prior  to  desensitization,  which  were
aintained  during  hospitalization.  The  use  of  beta-blockers
r  ACE  inhibitors  was  not  allowed.  Procedures  were  also
erformed  for  respiratory/cardiovascular  assessment:
.  Vital  signs  every  hour  during  desensitization  and,  when-
ever  necessary;
. Basal  FEV1  through  spirometry.  A  20%  reduction  in  FEV1
was  pre-calculated  by  multiplying  FEV1  in  liters  by  0.8;
.  Previous  spirometry  (FEV1)  at  each  dose  of  aspirin,  at
each  hour  and  when  necessary.  If  the  patient  had  severe
dyspnea  or  decrease  in  FEV1  >  20%,  salbutamol  nebuliza-
tion  was  performed;
.  If  SBP  <  90  mmHg,  adrenaline  1:1000  0.3  mL  was  adminis-
tered  IM;
.  Rhinorrhea,  nasal  congestion,  and  ﬂushing:  FEV1  and
blood  pressure  (BP)  were  checked  and  veriﬁed,  if  rhi-
norrhea  was  accompanied  by  a  decrease  in  FEV1  >  20%  or
systolic  BP  <  90  mmHg,  and  protocol  was  followed  as  pre-
viously  described.  For  rhinorrhea,  nasal  congestion,  or
ﬂushing  not  accompanied  by  the  abovementioned  symp-
toms,  promethazine  50  mg  IV  was  administered.
Aspirin  desensitization.
Dose
Day  1
8:00  AM  Aspirin  20  mg  orally
10:00 AM  Aspirin  40  mg  orally
12:00 PM  Aspirin  60  mg  orally
2:00 PM  Aspirin  81  mg  orally
Day 2
8:00  AM  Aspirin  81  mg  orally
10:00 AM  Aspirin  160  mg  orally
12:00 PM  Aspirin  325  mg  orally
2:00 PM  Aspirin  650  mg  orally
The  patient  was  observed  for  3  h  after  the  ﬁnal  dose,  and
hen  was  discharged  with  the  following  medications:
.  Aspirin  650  mg  every  12  h,  orally;
.  Proton  pump  inhibitor  or  H2  blocker  was  considered  for
gastric  protection;
.  Regularly  used  medications.
The  daily  dose  of  1300  mg  was  maintained  for  six  months,
nd  after  that,  the  dose  was  decreased  according  to  clinical
arameters  (mean  of  375--975  mg/day).  Because  the  desen-
itized  state  is  maintained  for  only  two  to  ﬁve  days  after
spirin  use  cessation,  when  the  use  is  below  325  mg/day  for
ore  than  48  h,  intake  should  not  be  resumed,  due  to  the
isk  of  severe  reactions.
Patients  maintained  the  previously  used  drugs  and  were
old  to  come  for  periodic  assessments  at  the  Outpatient
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linic  of  Rhinosinusitis  every  three  months  in  the  ﬁrst
emester,  and  every  six  months  thereafter.  At  these  return
onsultations,  the  patients  were  evaluated  for  the  presence
f  sinonasal  symptoms  (nasal  obstruction,  anterior  or  poste-
ior  rhinorrhea,  facial  pain,  hyposmia,  cacosmia,  and  other
inonasal  symptoms),  and  the  nasoﬁbroscopy  ﬁndings  (pres-
nce  of  polypoid  degeneration  in  the  ethmoid  roof,  middle
eatus,  polyps,  secretion).  The  mean  interval  between
ecurrence  requiring  surgery  before  and  after  desensitiza-
ion,  time  until  the  diagnosis  of  AERD  and  the  results  of
mmediate  hypersensitivity  skin  tests,  performed  to  assess
he  association  with  atopy,  were  also  evaluated.
A  group  of  eight  patients  undergoing  desensitization  did
ot  complete  the  procedure,  or  did  not  persist  with  the  later
se  of  the  drug.  Patients  who  refused  to  undergo  desensiti-
ation  or  were  lost  to  follow-up,  or  who  were  still  undergoing
ollow-up  for  a  period  less  than  a  year  after  desensitization
ere  not  included  in  this  study.
esults
atients  with  CRSwNP  and  moderate/severe  asthma  submit-
ed  to  EPSS  were  assessed.  Among  all  diagnosed  with  AERD,
eventeen  of  them,  who  had  already  been  submitted  to  at
east  one  surgery,  accepted  and  underwent  the  desensiti-
ation  protocol.  One  patient  was  lost  to  follow-up  and  was
xcluded  from  the  study.  Of  the  16  remaining  patients,  eight
D
A
b
Table  1  Patients  who  completed  ASA  desensitization.
Patient  Gender  Age  (years)  Age  at  desensitizatio
(years)
1  F  55.5  50.9  
2 F  55.9  54.2  
3 F  43.8  39  
4 F  61.1  59.9  
5 F  51.2  46.1  
6 M  32.6  30.5  
7 M  55  54  
8 F  44.1  42.1  
F, female; M, male.
Table  2  Symptoms  and  nasoﬁbroscopy  ﬁndings  in  eight  patients  
Before  desen
Symptoms
Nasal  obstruction  7  
Rhinorrhea (before/after)  6  
Facial pain  1  
Hyposmia/anosmia  7  
Cacosmia 1  
Nasal pruritus  3  
Nasoﬁbroscopy  ﬁndings
Secretion  3  
Polypoid degeneration  of  the  ethmoid  ceiling  --  
Polypoid degeneration  of  the  middle  meatus  --  
Polyps 8  Spies  JW  et  al.
ompleted  the  procedure,  while  eight  others  had  the  treat-
ent  interrupted.
Of  the  eight  patients  who  completed  one  year  of  desen-
itization,  there  were  two  males  and  six  females.  The  mean
ime  from  symptom  onset  and  AERD  diagnosis,  as  well  as
atients’  ages  at  the  start  of  desensitization  and  time  of
ollow-up  are  described  in  Table  1.  The  mean  follow-up  was
.1  years  after  desensitization  (ranging  between  one  and
ve  years).  Symptom  assessment  and  nasoﬁbroscopy  ﬁndings
efore  and  after  desensitization  are  shown  in  Table  2.
None  of  the  patients  followed  after  desensitization  had
 new  surgical  indication.  Eight  did  not  complete  or  did  not
ersist  with  desensitization.  There  was  a  predominance  of
omen  (six  women  and  two  men),  with  a  mean  age  of  50
ears,  9  months.  The  mean  number  of  surgeries  was  1.75
range  from  one  to  four  procedures)  prior  to  desensitiza-
ion.  Three  patients  did  not  complete  desensitization  due  to
dverse  reactions  and  decompensated  asthma.  Three  others
iscontinued  the  use  after  less  than  one  month  of  aspirin  in
ull  dose  due  to  asthma  worsening.  There  was  also  a  patient
ho  discontinued  use  due  to  suspected  dengue  fever  and
nother  abandoned  treatment  due  to  fear  of  a  new  surgery.iscussion
spirin  desensitization  is  an  alternative  that  has  shown  to
e  effective  in  the  management  of  patients  with  AERD.
n Time  until  diagnosis
of  AERD  (years)
New  surgical  indication
after  desensitization
14  --
14  --
10  --
8  --
19  --
6  --
5  --
8  --
undergoing  aspirin  desensitization  during  follow-up.
sitization  Three  months  Six  months  12  months
1  1  2
2  1  3
--  --  --
--  --  1
--  --  --
--  --  3
--  --  --
1  1  3
2  2  --
1  --  --
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Studies  have  shown  that  the  desensitization  results  in
signiﬁcant  improvement  of  all  AERD  symptoms,  reduction
of  rhinosinusitis,  better  control,  and  reduced  doses  of
corticosteroids  used  to  treat  asthma,  anosmia/hyposmia
improvement,19 decreased  need  for  revision  sinonasal
surgery,  improved  tomographic  image  and  quality  of  life
of  patients,  as  well  as  reduced  costs,  both  regarding
procedures  and  medications.19,20
Long-term  treatment  with  aspirin  causes  downregulation
of  IL-4  and  subsequent  downregulation  of  the  cysteinyl-
leukotriene  receptors  in  lymphocytes,  which,  ultimately,
lead  to  a  decrease  in  the  Th2  inﬂammatory  response.
Another  important  aspect  of  this  therapy  is  the  decrease
in  MMP-9  (matrix  metalloproteinase  9),  which  is  important
in  the  airway  remodeling  process.19 Desensitization  can  be
considered  the  ﬁrst  choice  of  treatment  for  patients  with
AERD  and  recalcitrant  nasal  polyposis,  need  for  repeated
sinus  surgery,  need  for  systemic  corticosteroids,  or  those
with  any  medical  condition  requiring  chronic  aspirin  use.21
The  recurrence  of  nasal  polyposis  after  surgery  is  almost
three-fold  higher  in  patients  with  AERD,  when  compared  to
those  without  it.22 Other  studies  have  shown  that  desensiti-
zation  increased  the  mean  length  of  surgical  reintervention
from  three  to  approximately  six  years,23,24 with  signiﬁ-
cant  improvement  in  quality  of  life,  olfactory  function,
decreased  nasal  polyps,  and  asthma  control.24 In  the  present
study,  all  eight  patients  that  maintained  desensitization  for
at  least  one  year  showed  signiﬁcant  improvement  of  clin-
ical  parameters  and  nasoﬁbroscopy  ﬁndings.  After  a  mean
follow-up  of  3.1  years,  no  patient  was  submitted  to  a  new
surgical  approach.
Desensitization  is  not  risk-free  and  requires  several
precautions  due  to  possible  complications.  Even  when  con-
ducted  in  a  hospital  under  stringent  medical  care  and
frequent  outpatient  consultations,  many  patients  do  not
tolerate  the  procedure.  This  represents  the  main  cause  of
patient  refusal  when  they  are  invited  to  undergo  desensi-
tization.  Berges-Gimeno  et  al.25 (2003)  found  that  67%  of
patients  beneﬁted  from  the  therapy  with  aspirin  during  a
one-year  follow-up  and  14%  discontinued  the  use  of  ASA  due
to  side  effects,  whereas  11%  discontinued  due  to  pregnancy
or  elective  surgery.  It  is  important  to  emphasize  its  correct
continuous  use.  If  patients  discontinue  treatment,  they  can-
not  re-start  the  medication  on  their  own,  because  of  the  risk
of  severe  reactions.
In the  present  study,  in  the  group  of  patients  who  discon-
tinued  desensitization,  three  of  eight  patients  were  unable
to  ﬁnish  it,  due  to  adverse  reactions  and  worsening  of
asthma.  The  other  three  had  uncontrolled  asthma  after
less  than  one  month  using  aspirin  625  mg  twice  daily,  which
required  discontinuation.  There  are  still  factors  that  can-
not  be  predicted  or  are  independent  from  medical  action,
such  as  what  occurred  with  a  patient  with  suspected  dengue
fever  who  had  to  interrupt  the  medication  due  to  the  risk  of
Reye’s  syndrome.
Desensitization  is  capable  of  altering  the  natural  course
of  AERD26 and  should  be  included  in  the  treatment  of
patients  with  the  disease27;  however,  it  should  not  be
considered  as  an  option  to  replace  a  new  surgical  inter-
vention.  The  main  goal  is  to  postpone  a  new  surgery
or  even  make  it  less  aggressive,  thereby  decreasing  the
risks  for  the  patient.  Another  goal  is  to  lessen  morbidity,
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hrough  symptom  improvement  and  decrease  in  acute
pisodes.  Although  this  was  not  a  randomized,  double-
lind,  placebo-controlled  trial,  this  study  showed  that
spirin  desensitization  is  an  effective  option  for  patients
ith  AERD  who  meet  the  indications  for  this  procedure.  It
epends  on  an  excellent  doctor--patient  relationship,  with
ull  commitment  by  the  patient  to  use  aspirin  uninterrupt-
dly;  the  patient  must  be  very  well  advised  regarding  all
otential  risks/side  effects  and  the  fact  that  treatment
essation  may  result  in  the  loss  of  all  that  has  been  gained,
ith  great  possibility  of  disease  recurrence.
onclusion
espite  the  small  sample  size,  aspirin  desensitization  has
hown  to  be  an  effective  alternative  treatment  for  patients
ith  poor  clinical  response.  More  studies,  performed  for
 longer  period  of  time,  are  necessary  to  better  evaluate
he  effectiveness  of  aspirin  desensitization  in  patients  with
ERD.
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